周四盘中，全球制药巨头辉瑞（PFE）股价大幅下挫，跌幅高达5.02%。这一显著跌幅引发了市场的广泛关注。
造成辉瑞股价暴跌的主要原因是投资银行高盛发布的最新研报。高盛分析师将辉瑞的评级从"买入"下调至"中性"，同时将目标价从32.00美元大幅下调至25.00美元。这一评级调整显著打击了投资者对辉瑞未来前景的信心，导致股价应声下跌。
值得注意的是，辉瑞作为全球最大的制药公司之一，年销售额接近500亿美元（不包括与新冠相关的产品销售额）。公司主要业务集中在处方药和疫苗领域，畅销产品包括肺炎球菌疫苗Prevnar 13、抗癌药物Ibrance和心血管治疗药物Eliquis。尽管辉瑞在全球市场占有重要地位，但此次高盛的评级下调无疑给公司股价带来了显著压力。投资者将密切关注辉瑞未来的业务发展和市场表现，以评估公司的长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.